brain bleed in people with atrial fibrillation (AF)
Protocol: STUDY00004192
Full Title
Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)
Description
This study enrolls people with atrial fibrillation (AF) who have had a recent brain bleed (with in 4 months). The purpose of this study is to compare the effects of apixaban (also known as Eliquis®) with aspirin in patients to see which is better in preventing strokes and death.

You will be in this study for up to 3 years. After the first visit, routine follow-up visits will occur every 3 months for a maximum of 3 years. Please contact the research team for more details about the details of the study. Study takes place at Gates Vascular Institute/Buffalo General Medical Center and UBMD Neruovascular Clinics.

Technical Description

To determine if apixaban is superior to aspirin for prevention of the composite
outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent
ICH and AF. Also, to determine if apixaban, compared with aspirin, results in better functional
outcomes as measured by the modified Rankin Scale.
Compensation: No
Eligibility
-Adults ages 18+.
-Diagnosed with Intracerebral hemorrhage (ICH).
-Have non-valvular atrial fibrillation or atrial flutter.
Age Group: Adults
Principal Investigator: AMIT KANDEL
Contact(s)
ANNEMARIE CRUMLISH
ac35@buffalo.edu
+1 716-859-7540
Want to Learn More?
Enrollment Update

Due to COVID-19, new enrollment in research studies will be greatly limited. If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry. View the guidance for research participants for additional information.

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.